title: Statin use and risk of lymphoid neoplasms: results from the European Case-Control Study EPILYMPH.
abstract: BACKGROUND
  Statins, drugs used to treat dyslipidemia, may have anticancer properties. We have evaluated lymphoma risk associated with regular statin use in an international case-control study.
  
  
  METHODS
  This case-control study included 2,362 cases of incident B- and T-cell lymphoma from Czech Republic, France, Germany, Ireland, Italy, and Spain and 2,206 hospital or population controls. Information on drug use, diagnosis at admission (for hospital controls), and putative risk factors for lymphoma was collected with personal interviews. Hospital controls admitted for diseases possibly entailing use of statins were excluded from the analysis.
  
  
  RESULTS
  The odds ratio for regular statin use was 0.61 (95% confidence interval, 0.45-0.84); all major lymphoma subtypes showed similarly decreased risks. Decreased risks were observed in all centers. Duration of statin use was not associated with a greater reduction in the risk of lymphoma. Use of other lipid lowering drugs, such as fibrates, did not significantly modify the risk of lymphoma (odds ratio, 0.75; 95% confidence interval, 0.44-1.27).
  
  
  CONCLUSIONS
  Statin use was associated with an important reduction in lymphoma risk, adding to the growing evidence of anticancer properties of this group of drugs. These results are reassuring for the increasing number of patients taking statins on a regular basis.
authors.affiliation: Servei d'Epidemiologia i Registre del Càncer, Institut Català d'Oncologia, Gran Via Km 2.7, 08907 L'Hospitalet de Llobregat, Autonomous University of Barcelona [corrected] Barcelona, Catalonia, Spain.
authors.forename: Joan
authors.initials: J
authors.lastname: Fortuny
authors.forename: Sílvia
authors.initials: S
authors.lastname: de Sanjosé
authors.forename: Nikolaus
authors.initials: N
authors.lastname: Becker
authors.forename: Marc
authors.initials: M
authors.lastname: Maynadié
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Cocco
authors.forename: Anthony
authors.initials: A
authors.lastname: Staines
authors.forename: Lenka
authors.initials: L
authors.lastname: Foretova
authors.forename: Martine
authors.initials: M
authors.lastname: Vornanen
authors.forename: Paul
authors.initials: P
authors.lastname: Brennan
authors.forename: Alexandra
authors.initials: A
authors.lastname: Nieters
authors.forename: Tomàs
authors.initials: T
authors.lastname: Alvaro
authors.forename: Paolo
authors.initials: P
authors.lastname: Boffetta
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D050171:Dyslipidemias / Q000188:drug therapy*; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D016015:Logistic Models; D016393:Lymphoma, B-Cell / Q000453:epidemiology* / Q000517:prevention & control; D016399:Lymphoma, T-Cell / Q000453:epidemiology* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D013997:Time Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors